New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec's ... MarketWatch (press release) ... and FAMPYRA(R) (prolonged-release fampridine tablets) -- the company will present results from investigational trials of its late-stage pipeline, including: BG-12, PEGylated interferon beta-1a, and daclizumab high-yield process (DAC HYP) for MS; ... |
